- Home
- CLW vs CGEN Comparison
CLW vs CGEN Comparison
Compare CLW & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLW | CGEN |
|---|---|---|
| Founded | 1926 | 1993 |
| Country | United States | Israel |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 201.8M |
| IPO Year | 2008 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CLW | CGEN |
|---|---|---|
| Price | $14.43 | $2.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $20.00 | $4.80 |
| AVG Volume (30 Days) | ★ 269.7K | 229.9K |
| Earning Date | 10-26-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.30 | $55.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $1.43 |
| 52 Week High | $23.59 | $3.24 |
Technical Indicators
Market Signals| Indicator | CLW | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 49.52 |
| Support Level | $12.21 | $1.98 |
| Resistance Level | $14.56 | $2.33 |
| Average True Range (ATR) | 0.97 | 0.09 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 43.93 | 73.68 |
Price Performance
Historical ComparisonAbout CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.